Reported Earlier, Telix Names David Gill Board Chair As Mark Nelson Steps Down From Interim Role

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.

FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading

https://www.fda.gov/media/195157/download

Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth

The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.

Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain